BioCryst Pharmaceuticals
BCRX
75 hedge funds and large institutions have $264M invested in BioCryst Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 13 closing their positions.
87% more call options, than puts
Call options by funds: $6.94M | Put options by funds: $3.7M
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
21% more capital invested
Capital invested by funds: $217M → $264M (+$46.2M)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
3% more funds holding
Funds holding: 73 → 75 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$10.2M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.35M |
| 5 |
Morgan Stanley
New York
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.48M |
| 2 |
DM
Deerfield Management
New York
|
-$4.84M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$4.53M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.81M |
| 5 |
VM
VHCP Management
New York
|
-$2.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
76
Bogle Investment Management
Newton Lower Falls,
Massachusetts
| – | -$2.81M | -386,089 | Closed |
|
77
Jane Street
New York
| – | -$1.32M | -181,665 | Closed |
|
|
EI
78
EAM Investors
Solana Beach,
California
| – | -$1.08M | -148,081 | Closed |
|
|
RFC
79
Russell Frank Company
Seattle,
Washington
| – | -$697K | -95,795 | Closed |
|
80
Nomura Holdings
Tokyo,
Japan
| – | -$677K | -92,836 | Closed |
|
|
HCMT
81
Highland Capital Management (Texas)
Dallas,
Texas
| – | -$675K | -92,680 | Closed |
|
|
SIM
82
SSI Investment Management
Los Angeles,
California
| – | -$437K | -60,110 | Closed |
|
|
LMF
83
LMR Master Fund
Grand Cayman,
Cayman Islands
| – | -$159K | -21,844 | Closed |
|
|
VKH
84
Virtu KCG Holdings
New York
| – | -$85K | -11,614 | Closed |
|
|
CAM
85
ClariVest Asset Management
San Diego,
California
| – | -$72K | -9,900 | Closed |
|
86
Public Employees Retirement Association of Colorado
Denver,
Colorado
| – | -$70K | -9,630 | Closed |
|
87
Ameriprise
Minneapolis,
Minnesota
| – | -$22K | -3,000 | Closed |
|
|
FNYS
88
First New York Securities
New York
| – | -$7K | -994 | Closed |
|
BCRX Hedge Fund Activity: Q4 2013 in Review
75 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2013, worth a combined $264M — up 21% from $217M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BCRX positions and 13 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was RA Capital Management, cutting an estimated $9.48M.
- 75 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2013, up from 73 in Q3 2013.
- Funds reported $264M of BioCryst Pharmaceuticals stock for Q4 2013, up 21% quarter-over-quarter.
- 15 funds opened new BioCryst Pharmaceuticals positions in Q4 2013 and 13 closed out, a net change of +2 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $16.3M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2013 was RA Capital Management, an estimated $9.48M sold.
Based on aggregated 13F filings for Q4 2013.